
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc demonstrates a strong growth trajectory within its Precision Diagnostics and Radiopharmaceutical Oncology segments, indicated by an increase in POSLUMA's market share and revenue projections for PSMA PET imaging. The anticipated enhancements from the new Pylarify formulary, including a 50% increase in batch size and three years of TPT eligibility, are expected to reinvigorate growth from late 2026 onward, tapping into previously unmet demand. Additionally, potential growth and margin contributions from non-Pylarify segments may further bolster earnings, positively influencing the company's financial outlook for 2026 and beyond.
Bears say
Lantheus Holdings Inc is facing a negative outlook as it experiences slower growth compared to its profitable SMID MedTech peers, with projections for 2025-2026 indicating a decline in Pylarify revenue growth. The company's recent performance revealed a significant miss in Pylarify revenue, which totaled $260 million, reflecting an 8% year-over-year decrease and falling short by approximately $14 million against consensus estimates. Additionally, the overall unit growth was disappointing, registering only 2% year-over-year and facing a detrimental 10% price headwind during the quarter, further complicating its growth trajectory.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares